NCT03162510 (SOLAR) is a Phase 1 clinical trial of Oxaliplatin in Gastric Cancer in Situ, sponsored by National Health Research Institutes, Taiwan.

Who is sponsoring NCT03162510?

NCT03162510 is sponsored by National Health Research Institutes, Taiwan.

What drugs are being tested in NCT03162510?

Interventions in NCT03162510: Oxaliplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel, S-1, LV.

What condition does NCT03162510 study?

NCT03162510 studies Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers.

Is NCT03162510 still recruiting?

NCT03162510 is currently completed. Last updated 7 April 2022.

Last reviewed 2022-04-07 · How we verify

NCT03162510: SOLAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

Completed Phase 1 Last updated 7 April 2022

What this trial tests

Phase 1 trial testing Oxaliplatin in Gastric Cancer in Situ in 18 participants. Completed in 31 January 2022.

Timeline

26 June 2018

Primary endpoint
7 June 2021

31 January 2022

Quick facts

Lead sponsor	National Health Research Institutes, Taiwan
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	26 June 2018
Primary completion	7 June 2021
Estimated completion	31 January 2022
Sites	1 location across Taiwan

Drugs / interventions tested

Oxaliplatin (Oxaliplatin) — full drug profile →
Albumin-Bound Paclitaxel /nab-Paclitaxel — full drug profile →
S-1 — full drug profile →
LV — full drug profile →

Conditions studied

Gastric Cancer in Situ — all drugs for Gastric Cancer in Situ →
Pancreatic Cancers — all drugs for Pancreatic Cancers →
Biliary Cancers — all drugs for Biliary Cancers →

Sponsor

National Health Research Institutes, Taiwan

Who can join

Adults 20 to 70, any sex, with Gastric Cancer in Situ or Pancreatic Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of the study is to determine the maximal tolerated dose (MTD) of Oxaliplatin in this phase I study. The secondary objectives are to determine the response rate, progression free survival, overall survival, and safety profiles. Eligible patients will receive a triplet chemotherapy consisting of nab-paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, plus oral S-1 35mg/m2 and Leucovorin 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma.
Yang SH, Lee JC, Chen BB, Kuo SH, et al · · 2022 · cited 1× · PMID 35572526 · DOI 10.3389/fimmu.2022.870406
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study.
Tsai HJ, Yang SH, Hsiao CF, Kao HF, et al · · 2024 · PMID 38902994 · DOI 10.1093/oncolo/oyae109

Verify or expand the search:

Other trials of Oxaliplatin

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other National Health Research Institutes, Taiwan trials

Trials by the same sponsor.

NCT07579832 — Quantitative Monitoring of Disability Care Quality for Long-Term Care Facilities 2 · NA · not yet recruiting
NCT06981637 — Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Contr · Phase 2 · recruiting
NCT07177365 — Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressiv · NA · not yet recruiting
NCT07138261 — Taiwanese Anaplastic Thyroid Cancer Registry · not yet recruiting
NCT07151365 — Plant-based Diets and Healthy Aging · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03162510 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Health Research Institutes, Taiwan
Last refreshed: 7 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03162510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing